Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M558Revenue (TTM) $M65.4Net Margin (%)-61.7Altman Z-Score23.1
Enterprise Value $M149EPS (TTM) $-0.3Operating Margin %-65.9Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.3Pre-tax Margin (%)-61.7Higher ROA y-yY
Price/Book1.410-y EBITDA Growth Rate %-34.7Quick Ratio29.9Cash flow > EarningsN
Price/Sales16.75-y EBITDA Growth Rate %-32.7Current Ratio29.9Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-9.0Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-9.5Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M137ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ACHN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ACHNJoel Greenblatt 2016-09-30 Sold Out -0.02%$7.63 - $9.29
($8.5)
$ 4.20-51%Sold Out0
ACHNJoel Greenblatt 2016-06-30 Reduce-0.03%$7.48 - $9.86
($8.57)
$ 4.20-51%Reduce -65.39%191,792
ACHNJoel Greenblatt 2016-03-31 Buy 0.05%$5.63 - $10.79
($7.36)
$ 4.20-43%New holding554,125
ACHNFirst Eagle Investment 2014-03-31 Sold Out -0.0054%$3.08 - $4.2
($3.51)
$ 4.2020%Sold Out0
ACHNFirst Eagle Investment 2013-12-31 Buy 0.01%$2.43 - $3.46
($2.9)
$ 4.2045%New holding600,000
ACHNGeorge Soros 2012-06-30 Sold Out -0.04%$5.94 - $10.95
($7.34)
$ 4.20-43%Sold Out0
ACHNGeorge Soros 2012-03-31 Reduce-0.09%$7.71 - $12.375
($9.57)
$ 4.20-56%Reduce -50.00%250,000
ACHNGeorge Soros 2011-12-31 Add0.16%$4.01 - $8
($6.15)
$ 4.20-32%Add 2132.14%500,000
ACHNGeorge Soros 2011-09-30 Buy $4.63 - $8.31
($6.37)
$ 4.20-34%New holding22,400
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ACHN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ACHN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FISHERMAN JASON SDirector 2016-12-22Buy10,000$3.966.06view
Fenton Mary KayCFO 2016-12-05Buy2,500$4.112.19view
Truitt JosephChief Commercial Officer 2016-12-02Buy3,500$4.063.45view
MANNING MARTHA EEVP, General Counsel 2016-12-02Buy2,500$4.092.69view
Deshpande MilindCEO 2016-12-02Buy2,500$4.063.45view
Barrish Joel CChief Scientific Officer 2016-12-02Buy2,500$4.063.45view
Apelian DavidChief Medical Officer 2015-12-30Sell10,000$10.5-60view
Fenton Mary KayCFO 2015-12-28Sell43,500$10.08-58.33view
VITULLO NICOLEDirector 2015-11-11Sell550,000$10.17-58.7view
VITULLO NICOLEDirector 2015-09-25Sell9,310$8.22-48.91view

Quarterly/Annual Reports about ACHN:

News about ACHN:

Articles On GuruFocus.com
Steven Cohen Increases Position in Dynavax Oct 07 2016 
UBS and JMP Securities Downgrade Achillion Pharmaceuticals Inc.(ACHN) Following Johnson & Johnson (J May 21 2015 
Dycom Industries (DY) Surpasses Estimates; Achillion Pharma (ACHN) Inks Mega-Deal with Janssen May 20 2015 
Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 
Weekly CEO Sells Highlight: Achillion Pharmaceutical Inc, Protective Life Corp, Host Hotels & Resort Aug 25 2014 
Top 4 Insider Buys of Last Week Jun 10 2013 
Weekly CEO Sells Highlight: Achillion Pharmaceuticals Inc, Monster Beverage Corp, CarMax Inc, and Im Jan 23 2012 
Weekly CEO Sells Highlight: UNH, LRY, ACHN, RPM Jan 16 2012 

More From Other Websites
Achillion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACHN) : January 11, 2017 Jan 11 2017
Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US :... Jan 10 2017
Where are the opportunities for investors in health care? Jan 09 2017
Achillion Receives $15M from J&J for HCV Study Enrolment Dec 29 2016
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Dec 28 2016
Achillion Announces Clinical Milestone for the Advancement of JNJ-4178 in Phase 2B Development for... Dec 28 2016
Achillion Announces Clinical Milestone for the Advancement of JNJ-4178 in Phase 2B Development for... Dec 28 2016
These 5 Stocks Under $10 Could Make You a Lot of Money Dec 08 2016
Data Presented at American Society of Hematology Meeting Demonstrate Potential Advantages of Factor... Dec 05 2016
Has The Smart Money Found A Winner in Infoblox Inc (BLOX)? Dec 01 2016
Achillion, J&J to Initiate Phase IIb Study on HCV Combo Dec 01 2016
Achillion Announces Initiation of Patient Dosing by Janssen in a Global, Short Treatment-Duration... Nov 30 2016
Achillion Announces Initiation of Patient Dosing by Janssen in a Global, Short Treatment-Duration... Nov 30 2016
This Metric Says It May Be Time to Buy Achillion Pharmaceuticals, Inc. (ACHN) Nov 26 2016
Achillion Pharmaceuticals (ACHN) is Oversold: Can It Recover? Nov 21 2016
Blog Coverage GTx Inc. Enobosarm Achieves Stage 1 Milestone Nov 17 2016
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) to Ring The Nasdaq Stock Market Closing Bell Nov 14 2016
ACHILLION PHARMACEUTICALS INC Financials Nov 11 2016
Achillion (ACHN) Reports Narrower-Than-Expected Q3 Loss Nov 07 2016
8 Companies That Destroyed Shareholders This Week Nov 05 2016
Achillion Pharma upgraded by Chardan Capital Markets Nov 04 2016
Health Sector Down As Report of Industry Price Collusion Surfaces Nov 03 2016
Achillion Reports Third Quarter 2016 Financial Results And Provides Update On Clinical Programs Nov 03 2016
Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen's Phase 2 Trial... Sep 23 2016
Achillion Announces 100% SVR Reported in Janssen's Phase 2a Trial Evaluating Triple Combination of... Sep 09 2016
Achillion to Present at Two Upcoming Investor Conferences Sep 01 2016
Achillion Reports Second Quarter 2016 Financial Results Aug 04 2016
Achillion to Present at Three Upcoming Investor Conferences Jun 01 2016
Achillion Reports First Quarter 2016 Financial Results and Provides Update on Clinical Programs May 03 2016
Achillion to Present at the Deutsche Bank 41st Annual Health Care Conference Apr 28 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)